Dr. Iacoboni on improving CAR T-cell therapy outcomes in lymphoma
Gloria Iacoboni, MD, PhD, a hematologist at Vall d’Hebron University Hospital in Barcelona, Spain, spoke with Dr. James Day, a clinical research training
SOHO UK
Cellular Therapy
Lymphoma
Aggressive B-Cell Lymphomas
News
SOHO Insider Podcast
Community Oncology News
Leukemia
Acute Lymphoblastic Leukemia
Lymphoma
Aggressive B-Cell Lymphomas
Multiple Myeloma
Myelodysplastic Syndromes
Myeloproliferative Neoplasms
News
Drs. Krish Patel and Gwen Nichols join SOHO Insider community oncology series
SOHO Insider is pleased to announce two new upcoming sessions in our Community Oncology Brown Bag Series, hosted by Loretta J. Nastoupil, MD.
Trending now
ASH 2025
Leukemia
Acute Lymphoblastic Leukemia
News
Video Interviews
Drs. Zheng and Bona discuss financial toxicity in pediatric ALL
Daniel Zheng, MD, a pediatric oncologist at the Children's Hospital of Philadelphia, and Chiara Bona, MD, a pediatric oncologist at Dana-Farber Boston Children's
SOHO UK
Leukemia
Acute Lymphoblastic Leukemia
Multiple Myeloma
Myelodysplastic Syndromes
News
Video Interviews
Dr. Jessica Manson discusses multidisciplinary HLH management at SOHO UK
Dr. Manson covers the importance of treating the underlying driver of HLH to prevent recurrence and improve patient outcomes. She also highlights resources
Leukemia
Chronic Lymphocytic Leukemia
Lymphoma
Indolent B-Cell Lymphomas
News
China NMPA approves pirtobrutinib in relapsed/refractory CLL/SLL
The approval is based on the phase 3 BRUIN CLL-321 trial, the first randomized study in patients pre-treated with a covalent BTK inhibitor.
Cellular Therapy
Multiple Myeloma
News
FDA accepts NDA for iberdomide in relapsed/refractory myeloma
Iberdomide is the first in a new class of medicines called cereblon E3 ligase modulator (CELMoD) agents, which utilize targeted protein degradation to
Lymphoma
Aggressive B-Cell Lymphomas
News
FDA accepts NDA for tirabrutinib in relapsed or refractory PCNSL
The filing was supported by results from the phase 2 PROSPECT study, which demonstrated an overall response rate of 67 percent and a
Multiple Myeloma
News
FDA approves teclistamab combo in relapsed myeloma
In a phase 3 clinical trial, the combination showed significant improvements in progression-free survival and overall survival compared with the standard of care.
Myeloproliferative Neoplasms
Polycythemia Vera
News
FDA grants priority review to rusfertide in polycythemia vera
Results from the phase 3 VERIFY study supported the filing, showing that the drug improved hematocrit levels and lowered the frequency of required
SOHO UK
Cellular Therapy
Acute Lymphoblastic Leukemia
Aggressive B-Cell Lymphomas
A view from SOHO UK: navigating the challenges and complexity of haematology
While we cannot ignore the wider challenges facing the NHS, the SOHO UK programme highlights the extraordinary pace of progress in haematology. Alongside